Delisting risk
Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
$4.27
Pre-market−0.14 (−3.06%)
At close$4.41(+0.80%)
Something off on this page? Send us feedback.
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Jun 2026 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | — | — | — | — | — | — | — |